Search Results - "Heijdra, J. M."

Analysis of current perioperative management with Haemate® P/Humate P® in von Willebrand disease: Identifying the need for personalized treatment by Hazendonk, H. C. A. M., Heijdra, J. M., de Jager, N. C. B., Veerman, H. C., Boender, J., van Moort, I., Mathôt, R. A. A., Meijer, K., Laros‐van Gorkom, B. A. P., Eikenboom, J., Fijnvandraat, K., Leebeek, F. W. G., Cnossen, M. H.

“…Introduction Patients with Von Willebrand disease (VWD) are regularly treated with VWF‐containing concentrates in case of acute bleeding, trauma and dental or…”
Get full text

Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations by Janssen, Alexander, Bennis, Frank C, Cnossen, Marjon H, Mathôt, Ron A A

“…This work focusses on extending the deep compartment model (DCM) framework to the estimation of mixed-effects. By introducing random effects, model predictions…”
Get full text

Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery by Preijers, T., Hazendonk, H. C. A. M., Liesner, R., Chowdary, P., Driessens, M. H. E., Hart, D., Keeling, D., Laros‐van Gorkom, B. A. P., Meer, F. J. M., Meijer, K., Fijnvandraat, K., Leebeek, F. W. G., Collins, P. W., Cnossen, M. H., Mathôt, R. A. A., Kruip, M. J. A. H., Polinder, S., Lock, J., Moort, I., Heijdra, J. M., Nederlof, A., Jager, N., Coppens, M., Peters, M., Tamminga, R. Y. J., Brons, P., Eikenboom, H. C. J., Schutgens, R. E. G., Fischer, K., Zwaan, C. M., Vliet, I.

“…Essentials Factor IX (FIX) dosing using body weight frequently results in under and overdosing during surgery. We aimed to establish a population…”
Get full text

Long-term cost-effectiveness of case-finding and mass-screening for coeliac disease in children by Heijdra Suasnabar, J M, Meijer, C R, Smit, L, van Overveld, F, Thom, H, Keeney, E, Mearin, M L, van den Akker-van Marle, M E

“…Celiac disease (CD) is a common yet underdiagnosed autoimmune disease with substantial long-term consequences. High-accuracy point-of-care tests (POCTs) for CD…”
Get full text

Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study by Heijdra, Jessica M, Al Arashi, Wala, de Jager, Nico C B, Cloesmeijer, Michael E, Bukkems, Laura H, Zwaan, Christian M, Leebeek, Frank W G, Mathôt, Ron A A, Cnossen, Marjon H, Cnossen, MH, Leebeek, FWG, Fijnvandraat, K, Mathôt, RAA, Meijer, K, Kruip, MJHA, Polinder, S, Coppens, M, Tamminga, RYJ, Laros-van Gorkom, BAP, Brons, P, Schols, SEM, van der Meer, FJM, Eikenboom, HCJ, Schutgens, REG, Fischer, K, Heubel-Moenen, F, Nieuwenhuizen, L, Ypma, P, Driessens, MHE, Zwaan, CM, van Vliet, I, Collins, PW, Liesner, R, Chowdary, P, Keeling, D, Lock, J, Hazendonk, HCAM, van Moort, I, Preijers, T, Heijdra, JM, de Jager, NCB, Goedhart, MCHJ, Bukkems, LH, Al Arashi, W, Cloesmeijer, ME, Janssen, A

“…IntroductionVon Willebrand disease (VWD) is a bleeding disorder, caused by a deficiency or defect of von Willebrand factor (VWF). In case of medical procedures…”
Get full text